PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2026

  • ID: 4382373
  • Report
  • Region: Global
  • 203 pages
  • GlobalData
1 of 5

FEATURED COMPANIES

  • Armetheon
  • Bayer
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Daiichi-Sankyo
  • Ionis Therapeutics
  • MORE
PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2026

Summary

Venous thromboembolism (VTE) is a disease that includes a myriad of life-threatening disorders ranging from pulmonary embolism (PE) to deep vein thrombosis (DVT). The therapeutic landscape for VTE is divided into the VTE treatment setting and VTE primary prophylaxis, which is further divided into the prophylaxis for total knee replacement (TKR) and total hip replacement (THR) patients, as well as for acute medically ill patients. Antithrombotic therapy represents the cornerstone treatment strategy for all VTE patients. Presently, the established vitamin K antagonists (VKA) and low molecular weight heparins (LMWH) are the most widely prescribed drugs for VTE treatment and prophylaxis, where the historical dominance of these therapies has been the most prominent barrier towards VTE market evolution and growth.

It is estimated that sales of venous thromboembolism (VTE) therapeutics were approximately $1.95B across the seven major markets (7MM) in 2016, which includes the US, the five major European markets (5EU: France, Germany, Italy, Spain, and UK), and Japan. In the 2016 base year, 25% of market shares were attributed to the VTE treatment setting ($497M) and 75% to VTE primary prophylaxis treatments ($1.45B).

By 2026, it is expected that the VTE market to grow at a strong Compound Annual Growth Rate (CAGR) of 3.87%, reaching sales of $2.85B by the end of the forecast period. The main market contributing to the sustained growth over this forecast is the US, contributing $1.43B in sales in 2016, a figure that is anticipated to increase at a CAGR of 3.08% to $1.94B by 2026. Over this forecast, the most prominent wave of sales increases comes from the novel oral anticoagulant (NOAC) class, which is expected to peak at $1.04B in global sales by 2022, reflecting a 10-year CAGR of 3.91% by 2026, despite the generic erosion of several key players.

Major drivers of VTE market growth over the forecast period are the -
  • Increase in patient shares towards the NOACs due to increased confidence among physicians about using these novel therapies.
  • Launch of betrixaban for extended-duration prophylaxis in acute medically ill patients.
  • Launch of the first Factor XI inhibitor, IONIS-FXIRX.
  • Increase in the global prevalence of VTE.
  • Launch of the Factor Xa reversal agents.
Major growth in the VTE market over the forecast period is caused by the rise in sales surrounding the VTE primary prophylaxis space, which increased from $1.45B in 2016 to $2.3B by 2026 at a CAGR of 4.66%. The VTE prophylaxis segment dominates the VTE space due to the much higher number of patients in need of prophylaxis compared to the number of patients in need of VTE treatment.

The report "PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2026" provides an Overview of VTE, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.

In depth, this report provides the following:
  • Annualized VTE therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2015 and forecast for ten years to 2025.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the VTE therapeutics market.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
  • Analysis of the current and future market competition in the global VTE therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Companies mentioned in this report: Boehringer Ingelheim, Bayer, Janssen, BMS, Pfizer, Sanofi, Daiichi-Sankyo, Portola Pharmaceuticals, Ionis Therapeutics, Armetheon.

Scope
  • Overview of VTE, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
  • Annualized VTE therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2015 and forecast for ten years to 2025.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the VTE therapeutics market.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
  • Analysis of the current and future market competition in the global VTE therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to buy

The report will enable you to:
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
  • Develop business strategies by understanding the trends shaping and driving the global VTE therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global VTE therapeutics market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the global VTE therapeutics market from 2016-2026.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Armetheon
  • Bayer
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Daiichi-Sankyo
  • Ionis Therapeutics
  • MORE
1 Table of Contents
2 Executive Summary
2.1 Sales for Venous Thromboembolism by Region, 2016-2026
2.2 VTE Primary Prophylaxis Treatments Will Promote Market Growth
2.3 Big Pharma Fuels Confidence in VTE Treatments via CV Label Expansions
2.4 Betrixaban to Acquire Critical Market Position by Addressing Unmet Needs
2.5 Opportunities Remain: The VTE Market Requires a Transformational Therapy
2.6 What Do Physicians Think?
3 Introduction
3.1 Catalyst
3.2 Related Reports
4 Disease Overview
4.1 Etiology and Pathophysiology
4.1.1 Etiology
4.1.2 Pathophysiology
4.2 Symptoms
4.3 Prognosis
4.4 Quality of Life
5 Epidemiology
5.1 Disease Background
5.2 Risk Factors and Comorbidities
5.3 Global and Historical Trends
5.4 Forecast Methodology
5.4.1 Sources
5.4.2 Forecast Assumptions and Methods
5.5 Epidemiological Forecast for VTE (2016-2026)
5.5.1 Diagnosed Incident Cases of Pulmonary Embolism
5.5.2 Diagnosed Incident Cases of Deep Vein Thrombosis
5.5.3 Diagnosed Incident Cases of VTE
5.5.4 Age-Specific Diagnosed Incident Cases of VTE
5.5.5 Sex-Specific Diagnosed Incident Cases of VTE
5.5.6 One- and 10-Year First Time Recurrent Cases of VTE
5.5.7 Number of VTE Cases with Cancer as Comorbidity
5.5.8 Number of VTE Attacks
5.5.9 Number of Hospital Discharges Meeting Criteria for Medically Ill and Those at Risk for VTE
5.5.10 Number of Primary Total Knee Replacements and Revisions
5.5.11 Number of Hip Replacements
5.6 Discussion
5.6.1 Epidemiological Forecast Insight
5.6.2 Limitations of the Analysis
5.6.3 Strengths of the Analysis
6 Disease Management
6.1 Diagnosis Overview
6.2 Treatment Overview
6.2.1 Treatment Guidelines and Leading Prescribed Drugs
6.2.2 Clinical Practice
6.3 US
6.4 5EU
6.5 Japan
7 Competitive Assessment
7.1 Overview
7.2 Warfarin
7.2.1 Overview
7.2.2 Efficacy and Safety
7.2.3 SWOT Analysis
7.2.4 Forecast
7.3 Pradaxa (dabigatran)
7.3.1 Overview
7.3.2 Efficacy and Safety
7.3.3 SWOT Analysis
7.3.4 Forecast
7.4 Xarelto (rivaroxaban)
7.4.1 Overview
7.4.2 Efficacy and Safety
7.4.3 SWOT Analysis
7.4.4 Forecast
7.5 Eliquis (apixaban)
7.5.1 Overview
7.5.2 Efficacy and Safety
7.5.3 SWOT Analysis
7.5.4 Forecast
7.6 Savaysa (edoxaban)
7.6.1 Overview
7.6.2 Efficacy and Safety
7.6.3 SWOT Analysis
7.6.4 Forecast
7.7 Other Therapeutic Classes
7.7.1 Heparins
7.7.2 Arixtra (fondaparinux)
7.7.3 Antiplatelets - Aspirin
8 Unmet Needs and Opportunity Assessment
8.1 Overview
8.2 Unmet Needs
8.2.1 Inadequate Prophylaxis in Acute Medically Ill Patients
8.2.2 Anticoagulation with Significantly Reduced Bleeding Risk
8.2.3 Optimal Therapy for Cancer Patients
8.2.4 Optimal Therapy for Patients with Moderate and Severe Renal Failure
8.2.5 Physician Education on Clinical Benefits of New Oral Anticoagulants among Orthopedic Surgeons in the US
8.2.6 Reversal Agents for New Oral Anticoagulants
8.3 Opportunity Assessment
8.3.1 Target Opportunity Profile - VTE Prophylaxis in Acute Medically Ill Patients
8.3.2 Target Opportunity Profile - VTE Patients with Cancer
8.3.3 Target Opportunity Profile - VTE Patients with Renal Impairment
8.3.4 Target Opportunity Profile - VTE Prophylaxis in THR and TKR Patients
9 Pipeline Assessment
9.1 Overview
9.2 Promising Drugs in Clinical Development
9.3 Betrixaban
9.3.1 Overview
9.3.2 Efficacy
9.3.3 Safety
9.3.4 Dosing and Formulation
9.3.5 Potential Clinical and Commercial Positioning
9.3.6 SWOT Analysis
9.3.7 Forecast
9.4 Xarelto (rivaroxaban)
9.4.1 Overview
9.4.2 Efficacy and Safety
9.4.3 Dosing and Formulation
9.4.4 Potential Clinical and Commercial Positioning
9.4.5 SWOT Analysis
9.4.6 Forecast
9.5 IONIS-FXIRX
9.5.1 Overview
9.5.2 Efficacy
9.5.3 Safety
9.5.4 Dosing and Formulation
9.5.5 Potential Clinical and Commercial Positioning
9.5.6 SWOT Analysis
9.5.7 Forecast
9.6 Tecarfarin
9.6.1 Overview
9.6.2 Efficacy
9.6.3 Safety
9.6.4 Dosing and Formulation
9.6.5 Potential Clinical and Commercial Positioning
9.6.6 SWOT Analysis
9.6.7 Forecast
9.7 Promising Drugs in Early-Stage Development
9.7.1 DS-1040
9.7.2 BAY-1213790
9.7.3 BMS-262084
9.7.4 GMI-1271
9.7.5 EP-7041
9.7.6 GC2107
9.7.7 Ichorcumab (JNJ-375)
9.7.8 CSL-312
9.8 Other Drugs in Development
10 Current and Future Players
10.1 Overview
10.2 Trends in Corporate Strategy
10.3 Boehringer Ingelheim
10.3.1 Overview
10.3.2 Portfolio Assessment
10.4 Bayer
10.4.1 Overview
10.4.2 Portfolio Assessment
10.5 Janssen
10.5.1 Overview
10.5.2 Portfolio Assessment
10.6 Bristol-Myers Squibb
10.6.1 Overview
10.6.2 Portfolio Assessment
10.7 Pfizer
10.7.1 Overview
10.7.2 Portfolio Assessment
10.8 Daiichi-Sankyo
10.8.1 Overview
10.8.2 Portfolio Assessment
10.9 Portola Pharmaceuticals
10.9.1 Overview
10.9.2 Portfolio Assessment
10.10 Ionis Therapeutics
10.10.1 Overview
10.10.2 Portfolio Assessment
10.11 Armetheon
10.11.1 Overview
10.11.2 Portfolio Assessment
11 Market Outlook
11.1 Global Markets
11.1.1 Forecast
11.1.2 Drivers and Barriers - Global Issues
11.2 US
11.2.1 Forecast
11.2.2 Key Events
11.2.3 Drivers and Barriers
11.3 5EU
11.3.1 Forecast
11.3.2 Key Events
11.3.3 Drivers and Barriers
11.4 Japan
11.4.1 Forecast
11.4.2 Key Events
11.4.3 Drivers and Barriers
12 Appendix
12.1 Bibliography
12.2 Abbreviations
12.3 Methodology
12.3.1 Forecasting Methodology
12.3.2 Diagnosed Patients
12.3.3 Percent Drug-Treated Patients
12.3.4 Drugs Included in Each Therapeutic Class
12.3.5 Launch and Patent Expiry Dates
12.3.6 General Pricing Assumptions
12.3.7 Individual Drug Assumptions
12.3.8 Generic Erosion
12.3.9 Pricing of Pipeline Agents
12.4 Primary Research - KOLs Interviewed for this Report
12.5 Primary Research - Prescriber Survey
12.6 About the Authors
12.6.1 Analyst
12.6.2 Managing Analyst
12.6.3 Therapy Area Director
12.6.4 Epidemiologist
12.6.5 Global Director of Therapy Analysis and Epidemiology
12.6.6 Global Head and EVP of Healthcare Operations and Strategy
12.7 About
12.8 Contact
12.9 Disclaimer

List of Tables
Table 1: VTE: Key Metrics in the 7MM
Table 2: Symptoms of VTE
Table 3: Risk Factors and Comorbidities for Venous Thromboembolism
Table 4: 7MM, Diagnosed Incident Cases of PE, Men and Women, All Ages, N, Select Years, 2016-2026
Table 5: 7MM, Diagnosed Incident Cases of DVT, Men and Women, All Ages, N, Select Years, 2016-2026
Table 6: 7MM, Diagnosed Incident Cases of VTE, Men and Women, All Ages, N, Select Years, 2016-2026
Table 7: 7MM, One- and 10-Year Recurrent VTE Cases, Men and Women, All Ages, N, 2016
Table 8: Number of VTE Cases With Cancer Comorbidity, Men and Women, All Ages, N, 2016 and 2026
Table 9: 7MM, Number of VTE Attacks, Men and Women, All Ages, N, Select Years, 2016-2026
Table 10: 7MM, Number of Hospital Discharges Meeting Criteria for Medically Ill; Those at risk for VTE, Men and Women, Ages =40 Years, N, 2016
Table 11: 7MM, Number of Primary Total Knee Replacements and Revisions, Men and Women, Ages =15 Years, N, Select Years, 2016-2026
Table 12: 7MM, Number of Hip Replacements, Men and Women, Ages =15 Years, N, Select Years, 2016-2026
Table 13: Treatment Guidelines for VTE by Country
Table 14: Duration of Anticoagulation Therapy for Different VTE Types
Table 15: Most Prescribed Drugs or Drug Classes for VTE by Country, 2016
Table 16: Factors Influencing Anticoagulant Choice in Different Treatment Settings for VTE
Table 17: Country Profile - US
Table 18: Country Profile - 5EU
Table 19: Country Profile - Japan
Table 20: Leading Drugs for VTE Treatment and Prophylaxis, 2016
Table 21: Product Profile - Warfarin
Table 22: Warfarin SWOT Analysis, 2016
Table 23: Product Profile - Pradaxa
Table 24: Efficacy and Safety of Pradaxa in VTE Treatment
Table 25: Efficacy and Safety of Pradaxa in Long-Term Secondary VTE Prevention
Table 26: Efficacy and Safety of Pradaxa in Primary Prophylaxis for THR
Table 27: Pradaxa SWOT Analysis, 2016
Table 28: Product Profile - Xarelto
Table 29: Efficacy and Safety of Xarelto in VTE Treatment
Table 30: Efficacy and Safety of Xarelto in Long-Term Secondary VTE Prevention
Table 31: Efficacy and Safety of Xarelto in Primary Prophylaxis for TKR and THR
Table 32: Xarelto SWOT Analysis, 2016
Table 33: Product Profile - Eliquis
Table 34: Efficacy and Safety of Eliquis in VTE Treatment
Table 35: Efficacy and Safety of Eliquis in Long-Term Secondary VTE Prevention
Table 36: Efficacy and Safety of Eliquis in Primary Prophylaxis for TKR and THR
Table 37: Eliquis SWOT Analysis, 2016
Table 38: Product Profile - Savaysa
Table 39: Efficacy and Safety of Savaysa in VTE Treatment
Table 40: Savaysa SWOT Analysis, 2016
Table 41: Commonly Used LMWHs
Table 42: Unmet Need and Opportunity in VTE, 2016
Table 43: Target Opportunity Profile - VTE Prophylaxis in Acute Medically Ill Patients
Table 44: Target Opportunity Profile - VTE Patients with Cancer
Table 45: Target Opportunity Profile - VTE Patients with Renal Impairment
Table 46: Target Opportunity Profile - VTE Prophylaxis in THR and TKR
Table 47: Late-Stage Pipeline for VTE, 2016
Table 48: Product Profile - Betrixaban
Table 49: Betrixaban SWOT Analysis, 2016
Table 50: Product Profile - Xarelto
Table 51: Product Profile - IONIS-FXIRX
Table 52: IONIS-FXIRX SWOT Analysis, 2016
Table 53: Product Profile - Tecarfarin
Table 54: Tecarfarin SWOT Analysis, 2016
Table 55: Early-Stage Pipeline Products for VTE
Table 56: Ongoing Late-Stage Clinical Trials of the NOACs in VTE
Table 57: Key players in the VTE market
Table 58: Boehringer Ingelheim’s VTE Portfolio Assessment, 2016
Table 59: Bayer’s VTE Portfolio Assessment, 2016
Table 60: Janssen’s VTE Portfolio Assessment, 2016
Table 61: BMS’ VTE Portfolio Assessment, 2016
Table 62: Pfizer’s VTE Portfolio Assessment, 2016
Table 63: Daiichi Sankyo’s VTE Portfolio Assessment, 2016
Table 64: Portola’s VTE Portfolio Assessment, 2016
Table 65: Ionis’ VTE Portfolio Assessment, 2016
Table 66: Armetheon’s VTE Portfolio Assessment, 2016
Table 67: VTE - Global Drivers and Barriers, 2016-2026
Table 68: Key Events Impacting Sales for VTE in the US, 2016-2026
Table 69: VTE - Global Drivers and Barriers in the US, 2016-2026
Table 70: Key Events Impacting Sales for VTE in the 5EU, 2016-2026
Table 71: VTE - Global Drivers and Barriers in the 5EU, 2016-2026
Table 72: Key Events Impacting Sales for VTE in Japan, 2016-2026
Table 73: VTE - Global Drivers and Barriers in Japan, 2016-2026
Table 74: Key Projected Launch Dates for VTE
Table 75: Key Historical and Projected Patent Expiry Dates for VTE
Table 76: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures
Figure 1: Global Sales for VTE by Country, 2016 and 2026
Figure 2: Etiology of VTE: Virchow’s Triad
Figure 3: 7MM, Age-Standardized Diagnosed Incidence of PE, All Ages, Cases per 100,000 Population, 2016
Figure 4: 7MM, Age-Standardized Diagnosed Incidence of DVT, All Ages, Cases per 100,000, 2016
Figure 5: 7MM, Sources Used to Forecast Diagnosed Incident Cases of PE and DVT, 2016
Figure 6: 7MM, Sources Used to Forecast the Number of Hospital Discharges that Meet the Criteria for Medically Ill. 2016
Figure 7: 7MM, Sources Used to Forecast Primary Total Knee Replacements and Hip Replacements. 2016
Figure 8: 7MM, Age-Specific Diagnosed Incident Cases of VTE, Men and Women, N
Figure 9: 7MM, Sex-Specific Diagnosed Incident Cases of VTE, All Ages, N, 2016
Figure 10: Treatment Algorithm for VTE
Figure 11: Site of Action of Current and Pipeline Treatments in VTE
Figure 12: Competitive Assessment of Late-Stage Pipeline Agents in VTE, 2016-2026
Figure 13: Clinical and Commercial Positioning of Betrixaban
Figure 14: Clinical and Commercial Positioning of Xarelto
Figure 15: Clinical and Commercial Positioning of IONIS-FXIRX
Figure 16: Clinical and Commercial Positioning of Tecarfarin
Figure 17: Company Portfolio Gap Analysis in VTE, 2016-2026
Figure 18: Global Sales for VTE by Country, 2016 and 2026
Figure 19: Global Sales for VTE Treatment by Drug Class, 2016 and 2026
Figure 20: Global Sales for VTE Prophylaxis by Drug Class, 2016 and 2026
Figure 21: Global Sales for NOACs, 2016-2026
Figure 22: Global Sales for VTE, 2016-2026
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Boehringer Ingelheim
  • Bayer
  • Janssen
  • Bristol-Myers Squibb
  • Pfizer
  • Daiichi-Sankyo
  • Portola Pharmaceuticals
  • Ionis Therapeutics
  • Armetheon
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll